# Genotype-Specific HPV E6/E7 mRNA Triage Improves Risk Stratification and Reduces Referrals in DNA-Positive ASC-US/LSIL: A Real-World Cohort from Nordland, Norway

**Authors:** Khalid Al-Shibli, Dat Tan Nguyen, Hiba Abdul Latif Mohammed, Sveinung Wergeland Sørbye

PMC · DOI: 10.3390/pathogens15020178 · 2026-02-06

## TL;DR

A new test using HPV E6/E7 mRNA improves cervical cancer risk assessment and reduces unnecessary procedures in women with uncertain HPV DNA results.

## Contribution

A genotype-specific HPV E6/E7 mRNA test is shown to improve risk stratification and reduce referrals in DNA-positive ASC-US/LSIL cases.

## Key findings

- 44.6% of HPV DNA-positive ASC-US/LSIL women tested positive for E6/E7 mRNA.
- mRNA triage reduced colposcopy referrals by 55% while maintaining detection of CIN2+ lesions.
- Genotype-specific PPVs were highest for HPV16, HPV18, HPV31, and HPV33.

## Abstract

HPV DNA–positive women with ASC-US/LSIL cytology represent a heterogeneous risk group in cervical screening and require efficient triage. We evaluated a genotype-specific 7-type HPV E6/E7 mRNA assay (PreTect HPV-Proofer 7; types 16/18/31/33/45/52/58) in a real-world quality-assurance cohort at Nordland Hospital (Bodø, Norway). Among HPV-positive women with ASC-US/LSIL reflex cytology, 225 had sufficient residual liquid-based cytology material and a valid mRNA result; 175 had complete follow-up (2022–2025) and were included. Overall, 44.6% (78/175) were mRNA-positive (ASC-US 45.2%; LSIL 43.3%). For CIN2+, sensitivity was 63.4%, specificity 61.2%, PPV 33.3%, and NPV 84.5%; CIN2+ risk was 33.3% in mRNA-positive versus 15.5% in mRNA-negative women (RR 2.16, 95% CI 1.23–3.78). For CIN3+, risk was 14.1% versus 6.2%. Genotype-specific PPVs were highest for HPV33, HPV18, HPV16, and HPV31. In a referral simulation, mRNA-guided triage reduced baseline colposcopy referrals by 55% and decreased colposcopies per detected CIN2+ by ~30%, while 15 CIN2+ and 6 CIN3+ occurred in the mRNA-negative group and would be expected to be detected at 12-month follow-up among women with persistent HPV positivity. Genotype-aware HPV E6/E7 mRNA triage improves risk stratification and may increase screening efficiency.

## Linked entities

- **Diseases:** cervical cancer (MONDO:0002974)

## Full-text entities

- **Genes:** CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}
- **Diseases:** 31 (MESH:C564629), HIV co-infection (MESH:D015658), invasive carcinoma (MESH:D009361), ASC-US (MESH:D065309), NILM (MESH:D009370), infected (MESH:D007239), 45 (OMIM:616669), cytological abnormalities (MESH:D000014), Co-Infections (MESH:D060085), precancerous lesions (MESH:D011230), CIN2-3 (MESH:C537153), HPV infection (MESH:D030361), 18 (OMIM:615615), CIN3+ lesion (MESH:D009059), cervical carcinogenesis (MESH:D063646), adenocarcinoma in situ (MESH:D065311), cancer (MESH:D009369), 33 (MESH:C564468), cervical intraepithelial neoplasia (MESH:D002578), injury to (MESH:D014947), LSIL (MESH:D000081483), Cervical Cancer (MESH:D002583)
- **Species:** Human papillomavirus 16 (serotype) [taxon 333760], Homo sapiens (human, species) [taxon 9606], Human papillomavirus (species) [taxon 10566]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943658/full.md

---
Source: https://tomesphere.com/paper/PMC12943658